There are currently 140 different types of known blood cancers known, many of which are rare and life-threatening. Together, leukaemias, lymphomas and myelomas account for 7% of all cancers. However, a distinct lack of awareness means that blood cancers are not being treated as a priority health challenge at the EU level or by many national governments. This is producing severe gaps in healthcare delivery, such as delayed or misdiagnosis and inadequate access to new, innovative treatments and proper care for the people who need it the most.
The First EU Blood Cancer Policy Summit, organised by ECIPE in collaboration with Janssen and with the patronage of the Slovak Presidency, took place in Brussels on 27 September 2016. The event featured personal accounts of blood cancer from the patient and carer perspectives, as well as a policy discussion about what can be done at an EU and national level to address the challenges facing blood cancer patients and European healthcare systems at large.
The First European Blood Cancer Policy Summit coincided with Blood Cancer Awareness Month and aims to address policy options at the European level and make patient voices heard.